Your browser doesn't support javascript.
loading
Increasing Utilization of Extended Criteria Donor Hearts for Transplantation: The OCS Heart EXPAND Trial.
Schroder, Jacob N; Patel, Chetan B; DeVore, Adam D; Casalinova, Sarah; Koomalsingh, Kevin J; Shah, Ashish S; Anyanwu, Anelechi C; D'Alessandro, David A; Mudy, Karol; Sun, Benjamin; Strueber, Martin; Khaghani, Asghar; Shudo, Yasuhiro; Esmailian, Fardad; Liao, Kenneth; Pagani, Francis D; Silvestry, Scott; Wang, I-Wen; Salerno, Christopher T; Absi, Tarek S; Madsen, Joren C; Mancini, Donna; Fiedler, Amy G; Milano, Carmelo A; Smith, Jason W.
Afiliación
  • Schroder JN; Duke University Hospital, Durham, North Carolina, USA. Electronic address: jacob.schroder@duke.edu.
  • Patel CB; Duke University Hospital, Durham, North Carolina, USA.
  • DeVore AD; Duke University Hospital, Durham, North Carolina, USA.
  • Casalinova S; Duke University Hospital, Durham, North Carolina, USA.
  • Koomalsingh KJ; University of Washington Medical Center, Seattle, Washington, USA.
  • Shah AS; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Anyanwu AC; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • D'Alessandro DA; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mudy K; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • Sun B; Minneapolis Heart Institute at Abbott Northwestern Hospital, Minneapolis, Minnesota, USA.
  • Strueber M; Baptist Medical Group, Memphis, Tennessee, USA.
  • Khaghani A; Queen Mary University of London, London, England.
  • Shudo Y; Stanford University Medical Center, Stanford, California, USA.
  • Esmailian F; Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Liao K; Baylor College of Medicine, Houston, Texas, USA.
  • Pagani FD; University of Michigan Medical Center, Ann Arbor, Michigan, USA.
  • Silvestry S; Advent Health, Orlando, Florida, USA.
  • Wang IW; Memorial Healthcare System, Hollywood, Florida, USA.
  • Salerno CT; University of Chicago Medicine, Chicago, Illinois, USA.
  • Absi TS; Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Madsen JC; Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Mancini D; Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Fiedler AG; University of California-San Francisco, San Francisco, California, USA.
  • Milano CA; Duke University Hospital, Durham, North Carolina, USA.
  • Smith JW; University of California-San Francisco, San Francisco, California, USA.
JACC Heart Fail ; 12(3): 438-447, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38276933
ABSTRACT

BACKGROUND:

Extended criteria donor (ECD) hearts available with donation after brain death (DBD) are underutilized for transplantation due to limitations of cold storage.

OBJECTIVES:

This study evaluated use of an extracorporeal perfusion system on donor heart utilization and post-transplant outcomes in ECD DBD hearts.

METHODS:

In this prospective, single-arm, multicenter study, adult heart transplant recipients received ECD hearts using an extracorporeal perfusion system if hearts met study criteria. The primary outcome was a composite of 30-day survival and absence of severe primary graft dysfunction (PGD). Secondary outcomes were donor heart utilization rate, 30-day survival, and incidence of severe PGD. The safety outcome was the mean number of heart graft-related serious adverse events within 30 days. Additional outcomes included survival through 2 years benchmarked to concurrent nonrandomized control subjects.

RESULTS:

A total of 173 ECD DBD hearts were perfused; 150 (87%) were successfully transplanted; 23 (13%) did not meet study transplantation criteria. At 30 days, 92% of patients had survived and had no severe PGD. The 30-day survival was 97%, and the incidence of severe PGD was 6.7%. The mean number of heart graft-related serious adverse events within 30 days was 0.17 (95% CI 0.11-0.23). Patient survival was 93%, 89%, and 86% at 6, 12, and 24 months, respectively, and was comparable with concurrent nonrandomized control subjects.

CONCLUSIONS:

Use of an extracorporeal perfusion system resulted in successfully transplanting 87% of donor hearts with excellent patient survival to 2 years post-transplant and low rates of severe PGD. The ability to safely use ECD DBD hearts could substantially increase the number of heart transplants and expand access to patients in need. (International EXPAND Heart Pivotal Trial [EXPANDHeart]; NCT02323321; Heart EXPAND Continued Access Protocol; NCT03835754).
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Corazón / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: JACC Heart Fail Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Trasplante de Corazón / Insuficiencia Cardíaca Tipo de estudio: Clinical_trials Límite: Adult / Humans Idioma: En Revista: JACC Heart Fail Año: 2024 Tipo del documento: Article